GenSight Biologics to Attend Chardan Gene Therapy Conference
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conference:
Chardan Inaugural Gene Therapy Conference
Tuesday,
October 10, 2017 – New York (USA)
Thomas Gidoin, Chief
Financial Officer, will present on October 10, 2017, at 1:00pm ET, at
the Westin New York Grand Central Hotel, and host investor meetings.
About GenSight Biologics
GenSight Biologics S.A. is a
clinical-stage biotechnology company discovering and developing novel
therapies for neurodegenerative retinal diseases and diseases of the
central nervous system. GenSight Biologics’ pipeline leverages two core
technology platforms, the Mitochondrial Targeting Sequence (MTS) and
optogenetics for retinitis pigmentosa, to help preserve or restore
vision in patients suffering from severe degenerative retinal diseases.
GenSight Biologics’ lead product candidate, GS010, is in Phase III
trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare
mitochondrial disease that leads to irreversible low vision and legal
blindness in teens and young adults. Using its gene therapy-based
approach, GenSight Biologics’ product candidates are designed to be
administered in a single treatment to each eye by intravitreal injection
to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003006259/en/
GenSight Biologics
Thomas Gidoin, +33 (0)1 76 21 72 20
Chief
Financial Officer
tgidoin@gensight-biologics.com
or
RooneyPartners
Media
Relations
Marion Janic, +1-212-223-4017
mjanic@rooneyco.com
or
The
Trout Group
Investor Relations
Chad Rubin, +1-646-378-2947
crubin@troutgroup.com
